On February 25, 2026 Kivu Bioscience, Inc., a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) for difficult-to-treat cancers, reported the presentation of new preclinical data for KIVU-305, its CEACAM5-targeted ADC, at World ADC London 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Kivu also announced another significant milestone with receipt of Human Research Ethics Committee (HREC) approval and Clinical Trial Notification (CTN) clearance in Australia to initiate a first-in-human clinical trial for KIVU-305. KIVU-305 will enter clinical development as Kivu’s second ADC program and further validate the company’s differentiated approach to designing ADCs with improved stability, potency, and tolerability.

"Presenting these data at World ADC London while also securing Australian HREC approval and CTN clearance marks a significant milestone for Kivu as we advance our second ADC candidate into the clinic," said Mohit Trikha, Ph.D., President and Chief Operating Officer, Kivu Bioscience. "KIVU-305 reflects our focus on improving ADC stability and tumor exposure while minimizing free payload toxicity, and we look forward to evaluating its potential to deliver a differentiated treatment option for patients with CEACAM5-expressing cancers."

CEACAM5 is broadly expressed across multiple solid tumors, including colorectal, pancreatic, and non-small cell lung cancers, where high expression is associated with poor prognosis and reduced overall survival. Despite prior validation of CEACAM5-directed ADCs, toxicity related to payload release has limited therapeutic benefit, highlighting the need for next-generation designs with improved stability and a wider therapeutic index.

KIVU-305 is a next-generation CEACAM5-targeted ADC composed of a humanized antibody conjugated via site-specific GlycoConnect technology to a HydraSpace-linked SYNtecan E topoisomerase inhibitor payload. The molecule incorporates an Fc-silenced antibody and optimized DAR4 configuration designed to enhance plasma stability, reduce Fc-mediated immune activity, enable higher intact ADC tumor exposure, and lower circulating free payload levels.

Preclinical results presented at World ADC London demonstrated:

Selective nanomolar binding to CEACAM5-positive tumor cells with efficient internalization
Potent target-dependent cytotoxicity and meaningful bystander killing activity
Strong anti-tumor efficacy across multiple cell-line-derived and patient-derived xenograft models, including chemotherapy-resistant tumors
Favorable pharmacokinetics, high plasma stability, and low free payload concentrations
Encouraging tolerability in repeat dose studies in non-human primates
These findings support advancement of KIVU-305 into a Phase 1 study evaluating safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in patients with advanced CEACAM5-expressing solid tumors.

About KIVU-305

KIVU-305 is a next-generation CEACAM5-targeted antibody-drug conjugate engineered to selectively bind tumor cells and deliver a potent topoisomerase inhibitor payload. Through site-specific conjugation, Fc-silencing, and optimized linker-payload design, KIVU-305 is designed to improve stability, reduce off-target toxicity, and potentially widen the therapeutic window in patients with advanced solid tumors.

(Press release, Kivu Bioscience, FEB 25, 2026, View Source [SID1234663014])

On February 25, 2026 Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, reported the pricing of its underwritten public offering of 17,647,058 shares of its common stock at a price to the public of $8.50 per share. The gross proceeds to Vir Biotechnology from the offering are expected to be $150 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Vir Biotechnology has granted the underwriters a 30-day option to purchase up to an additional 2,647,058 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the offering are being sold by Vir Biotechnology. Closing of the offering is expected to occur on February 27, 2026, subject to customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Goldman Sachs & Co. LLC, Leerink Partners, Evercore ISI and Barclays are acting as book-running managers for the offering.

The shares described above are being offered pursuant to an automatically effective shelf registration statement on Form S-3 that was filed with the U.S. Securities and Exchange Commission, or the SEC, on November 3, 2023. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering was filed with the SEC on February 24, 2026. The final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and may be obtained, when available, by contacting: Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866) 471-2526, or by email at [email protected]; Leerink Partners LLC, Attn: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or by email at [email protected]; Evercore Group L.L.C., Attn: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, or by telephone at (888) 474-0200, or by email at [email protected]; Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (888) 603-5847, or by email at [email protected]; or by accessing the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

(Press release, Vir Biotechnology, FEB 25, 2026, View Source [SID1234663013])

On February 25, 2026 IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, reported that the first patient has been enrolled in its Phase 1 dose escalation/expansion trial evaluating IDE034, an investigational PTK7/B7H3 bispecific TOP1 ADC. The company is planning to evaluate safety, tolerability and PK of IDE034 as a monotherapy in the Phase 1 trial, and also plans to test combinations with agents that target the DNA damage response (DDR) pathway, such as their proprietary PARG inhibitor, IDE161. Dosing of the first patient with IDE034 triggers a $5 million milestone payment from IDEAYA to Biocytogen, pursuant to the Option and License Agreement between the companies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This is an important milestone for IDE034 as well as our broader ADC/DDR portfolio focused on exploring combinations of highly selective TOP1 ADCs with agents targeting the DDR pathway. We are excited to begin dosing patients with IDE034, a B7H3/PTK7 bispecific ADC that has demonstrated promising signs of efficacy as a monotherapy and synergy in combination with IDE161 across several preclinical tumor cell models. IDE034 is our second proprietary TOP1 ADC, building on the progress we have made with IDE849, our DLL3 TOP1 ADC currently in Phase 1 for SCLC and NEC, and represents another potentially first-in-class therapy for cancer patients in need of new and improved treatment options," said Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences.

IDE034 is a potentially first-in-class B7H3/PTK7 bispecific TOP 1 ADC designed to be internalized only when its target antigens are co-expressed on the same tumor cell, which may enhance its selectivity and tolerability profile relative to monovalent antibody formats. IDEAYA estimates that B7H3/PTK7 are co-expressed in approximately 30-40% of certain large solid tumor types, including lung, breast, ovarian and colorectal cancers, while exhibiting minimal dual antigen expression in normal tissue. In preclinical tumor models, IDE034 has also demonstrated compelling combination potential with IDE161, the company’s oral PARG inhibitor, that suggests these mechanisms may synergize to enhance the efficacy and durability of TOP1 ADCs.

(Press release, Ideaya Biosciences, FEB 25, 2026, View Source [SID1234663012])

On February 25, 2026 Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, reported that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in four upcoming investor conferences, including fireside chats at two conferences.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The management team will participate in fireside chats and one-on-one meetings at the following conferences:

TD Cowen 46th Annual Health Care Conference – fireside chat on Wednesday, March 4, 2026, at 10:30 a.m. ET in Boston, MA

The Citizens Life Sciences Conference – fireside chat on Wednesday, March 11, 2026, at 8:25 a.m. ET in Miami, FL
The management team will participate in one-on-one meetings only at the following conferences:

UBS Biotech Summit Miami: Catalyst for Change on Monday, March 9, 2026, in Miami, FL

Jefferies Biotech on the Beach Summit on Tuesday, March 10, 2026, in Miami, FL
Live webcasts of each fireside chat will be available on the Investor Relations section of the Nuvation Bio website. An archived recording will be available for 90 days following each event.

(Press release, Nuvation Bio, FEB 25, 2026, View Source [SID1234663011])

On February 25, 2026 Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported its participation in the following investor conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TD Cowen Health Care Conference
March 4, 2026
11:50 a.m. ET / 8:50 a.m. PT

Leerink Partners Global Biopharma Conference
March 10, 2026
10:40 a.m. ET / 7:40 a.m. PT

Barclays Global Healthcare Conference
March 12, 2026
9:00 a.m. ET / 6:00 a.m. PT

Live audio webcasts will be available in the Investors section of Kura’s website at View Source, with archived replays available following all three events.

(Press release, Kura Oncology, FEB 25, 2026, View Source [SID1234663004])